Comparative Effects of 2 Diets in Veterans With the Metabolic Syndrome
NCT ID: NCT00852475
Last Updated: 2017-02-02
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
46 participants
INTERVENTIONAL
2010-02-28
2014-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Cardiometabolic risk factors will be determined by measuring several cardiovascular risk associated parameters including:
Biochemical measurements of lipids and inflammatory markers, body composition and VO2max (Specific Objective 1, Descriptive).
Postprandial response to a meal challenge and endothelial vasoreactivity (FMD) assessed by BART (Specific Objective 2, Physiological).
Determination of the effects on postheparin lipases and transfer protein activity, visceral adipose tissue (VAT) and homeostasis model assessment-estimated insulin resistance (HOMA-IR) (Specific Objective 3, Mechanistic)
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Dietary Intervention to Mitigate Post-Acute COVID-19 Syndrome
NCT05977179
Trial of Two Dietary Programs on Cardiometabolic Risk Factors in Subjects With Metabolic Syndrome
NCT01010841
Effectiveness of an Eight Week Online Mediterranean Based Diet
NCT01532258
Impact of High-fat Meals Varying in Fatty Acid Composition on Adipose and Systemic Metabolic-inflammatory Responses
NCT03712579
Effects of Monounsaturated Fatty Acids on Intestinal Lipid Metabolism in Insulin Resistant Subjects (MUFA )
NCT03872349
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
MUFA
Assignment to monounsaturated enriched diet with exercise. This represents the MUFA MOVE! program
MUFA MOVE! (Monounsaturated fatty enriched diet)
MUFA MOVE!diet and exercise program
PUFA
Assignment to polyunsaturated enriched diet with exercise. This represents the PUFA MOVE! program
PUFA MOVE! (Polyunsaturated fatty acid enriched diet)
PUFA MOVE! diet and exercise program
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
MUFA MOVE! (Monounsaturated fatty enriched diet)
MUFA MOVE!diet and exercise program
PUFA MOVE! (Polyunsaturated fatty acid enriched diet)
PUFA MOVE! diet and exercise program
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Waist circumference \>102 cm in men or \>88 cm women
* Treated Hypertension or Untreated Blood pressure \>130/85 and \< 160/100 mm Hg
* Treated Hyperglycemia or Untreated Fasting blood glucose (FBG) \>100 mg/dL (based on 2006 guidelines)
* Treated Hyperlipidemia or Untreated Triglycerides \> 150 mg/dL
* HDL-C \< 40 mg/dL men \< 50 mg/dL women
Exclusion Criteria
* Severe Pulmonary disease (Unable to walk on a treadmill at 2.5 mph or greater);
* Chronic renal insufficiency (Cr \> 2.5 mg/dL)
* Treated diabetes mellitus with FBG \> 180 mg/dL or HbA1C \>9g %
* Hematologic or malignant disorders
* Treated SBP \>160 mmHg and/or DBP \> 95 mmHg ;
* Treated TG \> 250 mg/dL
* Use of systemic vasodilators (e.g., nitrates)
* Morbid Obesity (BMI \> 50 kg/m2)
* Endocrine (thyroid) or metabolic disorders (unless treated and under control)
* Alcohol consumption greater than (2) 4-ounce glasses of table wine, (2) 12-oz bottles of beer or 2 shots of spirits in men or women
* Active IV drug abuse within the past 6 months
18 Years
80 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Maryland
OTHER
VA Office of Research and Development
FED
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Michael Miller, MD
Role: PRINCIPAL_INVESTIGATOR
VA Maryland Health Care System, Baltimore
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
VA Maryland Health Care System, Baltimore
Baltimore, Maryland, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HP-00040456
Identifier Type: OTHER
Identifier Source: secondary_id
CARA-030-08F
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.